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Abstract
Background and Purpose: Previous work by our group suggests smaller target volumes may result in equivalent
locoregional control for head and neck cancer. We evaluated whether smaller target volumes may also result in
improved normal tissue sparing.
Methods and Materials: Ten patients with Stage III-IV head and neck cancer were contoured and planned
according to target definitions in RTOG 0522 in a two dose level plan (RTOG), as well as a three dose level plan,
using smaller target volumes and an intermediate dose prescription (3Dose). Plans were compared for coverage of
targets and sparing of normal tissues
Results: The high dose target, elective nodal target, and total volume targeted were significantly smaller in 3Dose
plans (p < 0.001). There was no difference in volume receiving 100% of each prescription level in RTOG or 3Dose
plans. Mean dose to contralateral parotid, mandible, larynx, and inferior pharyngeal constrictor, and maximum dose
to brainstem were significantly lower in 3Dose plans. There was no significant difference in maximum dose to
spinal cord or volume of tissue not otherwise specified receiving 70 Gy.
Conclusions: Smaller target volumes with the addition of an intermediate dose volume results in improved
sparing of most normal tissues.
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Introduction
As treatments for locally advanced head and neck can-
cer (LAHNC) have become more aggressive through the
use of altered fractionation radiotherapy and concomi-
tant chemotherapy, concern has grown regarding the
risk of late toxicities in normal tissue.
The use of intensity-modulated radiation therapy
(IMRT) makes it possible to more effectively spare nor-
mal tissues, such as the parotid gland. Contouring and
construction of targets is extremely important in plan-
ning IMRT. Currently, no consensus exists regarding
the appropriate extent of margins for the clinical target
volume (CTV).
In a recent paper, we showed that there was no signif-
icant difference in locoregional control between ana-
tomic and volumetric expansions of gross tumor
volumes (GTV) [1]. Additionally, smaller volumetric
expansions appeared to result in similar locoregional
control as larger volumetric expansions. A number of
the patients reported in that study had a direct GTV to
planning target volume (PTV) expansion of 4-6 mm
without the use of a CTV-high dose; many of these
employed the use of a CTV-intermediate dose (CTV-ID)
to account for possible microscopic extension. No sig-
nificant difference in locoregional control was found for
PTV-high dose (PTV-HD) expansions of 4-6 mm, 10-15
mm, or >15 mm.
Theoretically, the definition of radiation targets should
impact the ability of a radiation oncologist to spare nor-
mal tissues. The recently completed Radiation Therapy
and Oncology Group trial 0522 (RTOG 0522) for
LAHNC employed target volumes intended to provide a
r e g i m e nt h a tw a sb a s e do nh i s t o r i c a lk n o w l e d g ea n d
could be implemented in a large cooperative group trial.
The target volumes stipulated by the RTOG 0522 proto-
col tend to render volumes that would be at the upper
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mentioned investigation of Caudell et al. In the current
report, we compare the RTOG 0522 target definitions
with smaller target volumes and their outcome on nor-
mal tissue sparing.
Materials and methods
Ten patients with LAHNC of the oropharynx, hypo-
pharyx, or larynx (Table 1) were identified who were
treated on RTOG 0522 (RTOG). RTOG contour defini-
tions are duplicated in Table 2. The same 10 patients
were also contoured and planned using smaller target
volumes and an intermediate dose level (3Dose, Table
2). The major difference in the 3Dose volumes was the
exclusion of a CTV for the high dose volume, with the
intermediate volume being identical to the high dose
target in the RTOG plan. The normal tissue contours,
GTV, and elective nodal volumes were identical between
patients’ plans. Identical PTV volumetric expansions
were utilized for each patient’s plan, though this did
vary between patients (3 - 5 mm). Each PTV was modi-
fied to exclude 1 - 5 mm of skin, and this was identical
for each patient’s plans. Figure 1 is an example of the
same patient illustrating the differences between RTOG
and 3Dose target volumes. Additionally, the glottic and
supraglottic larynx (GSL) and inferior pharyngeal con-
strictor (IPC) were contoured as per Eisbruch et al [2].
These structures were not entered into the optimization
algorithm but were reported.
Plans were generated using the Eclipse treatment
planning system (Eclipse 8.2.2, Varian Medical Systems,
Palo Alto, CA). Seven equally spaced coplanar 6 MV
beams with dynamic multileaf collimation were used for
IMRT planning in nine patients; one patient was
planned using nine equally spaced beams. The same
optimization objectives for normal tissues used for the
original RTOG plans were used for the 3Dose plans.
PTV optimization objectives were initially identical
between plans, but seven 3Dose plans needed revised
objectives to meet an author-imposed coverage require-
ment of at least 95% of the volume of PTV-elective dose
(PTV-ED) and PTV-intermediate dose (PTV-ID) receiv-
ing 100% of the prescribed dose. Target and normal tis-
sue goals from RTOG 0522 are listed in Table 3. As per
protocol, the PTV-HD received 70 Gy (2 Gy per frac-
tion), and PTV-ED received 56 Gy (1.6 Gy per fraction).
P T V - I Dw a sp r e s c r i b e d6 3G y( 1 . 8G yp e rf r a c t i o n ) .A l l
plans were normalized such that 95% of the volume of
PTV-HD received 70 Gy. The distributions of doses for
different planning techniques were assessed for statisti-
cally significant differences using the paired t-test.
Results
Volumes
PTV-HD was significantly larger using the RTOG defi-
nition (p < 0.001) compared with the 3Dose definition,
with a mean volume of 293.6 cc vs. 111.6 cc, respec-
tively (Table 4). PTV-ED and the total target volume (i.
e. PTV-HD + PTV-ID + PTV-ED) were also signifi-
cantly larger using the RTOG definition (p < 0.001 for
both comparisons), with a mean volume of 704.8 cc and
998.4 cc for the RTOG and 545.2 cc and 837.3 cc for
the 3Dose definitions, respectively (Table 4).
Doses
Coverage of PTV-HD was equivalent between the RTOG
and 3Dose target definitions at the 100% prescription iso-
dose (p = 0.86). Similarly, the volume of PTV-ED receiv-
ing 100% of the prescription was similar between
definitions (p = 0.84). High dose heterogeneity at the
110% and 115% levels for the PTV-HD were similar
between definitions, though there was a trend toward a
smaller percentage of the PTV-HD receiving 110% of the
dose for the 3Dose plans (p = 0.07). However, the hetero-
geneity at the 110% (p = 0.002) and 115% (p <0.001)
levels for PTV-ED were significantly lower using the
3Dose definitions. The volume of PTV-HD receiving 93%
of the prescription was significantly higher in the 3Dose
plans (p = 0.049) (Table 4). The volume of PTV-ED
receiving 93% of the prescription was higher in the
3Dose plans (p = 0.06). Mean doses to the PTV-HD and
PTV-ED were both significantly lower in the 3Dose plans
(Table 4). Additionally, the mean dose to the total target
volume was significantly less in the 3Dose plans, 62.8 Gy
compared with 64.7 Gy for the RTOG (p < 0.001). As a
corollary, the mean monitor units necessary to deliver
the plans was also less for the 3Dose definition plans,
1556 compared with 1675 for the RTOG (p = 0.01).
Normal Structures
In the 3Dose plans, the mean dose to the parotid (p =
0.01) and mandible (p = 0.001) were less than in the
Table 1 Patient Characteristics.
Patient Primary Site AJCC Stage
1 Hypopharynx T2N2c
2 Supraglottic Larynx T3N2c
3 Supraglottic Larynx T3N0
4 Base of Tongue T2N2a
5 Tonsil T3N2b
6 Tonsil T2N2b
7 Tonsil T4N2c
8 Tonsil T1N2a
9 Base of Tongue T4N2c
10 Hypopharynx T1N2b
Abbreviation: AJCC Stage = American Joint Committee on Cancer Staging 6
th
Edition
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RTOG 3Dose
PTV-HD (GTV + 1 cm) + 0.3 - 0.5 cm GTV + 0.5 cm
PTV-ID None (GTV + 1 cm) + 0.3 - 0.5 cm
PTV-ED ((GTV + 2 cm) + elective nodes)) + 0.3 - 0.5 cm Elective nodes + 0.3 - 0.5 cm
Abbreviations: RTOG = two dose level plan; 3Dose = three dose level plan; PTV-HD = high dose PTV; PTV-ID = intermediate dose PTV; PTV-ED = elective dose
PTV; GTV = gross tumor volume
Figure 1 Representative patient demonstrating variation in planning target volumes (PTV) for two dose (RTOG) and three dose
(3Dose) plans. Axial (A-B) and coronal (C-D) computed tomography images shown. The gross tumor volume (GTV, red line) is identical for each
plan. The PTV-high dose (PTV-HD, orange) and PTV-elective dose (PTV-ED, cyan) are presented for RTOG in A and C, respectively. These volumes
plus PTV-intermediate dose (PTV-ID, magenta) are displayed for 3Dose in B and D.
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parotid receiving 30 Gy (p = 0.03) and the volume of
mandible receiving 70 Gy (p = 0.03) were less in the
3Dose plans. Although doses to the GSL and the IPC
were not specifically constrained, the mean doses in
the 3Dose plans were still significantly less than
RTOG plans for both comparisons (p < 0.001 and p =
0.001, respectively). When excluding patients with lar-
yngeal or hypopharyngeal primary sites, the reductions
in mean dose to the GSL and the IPC were quite
large, 4.5 Gy and 5.3 Gy, respectively, in plans using
3Dose target volumes. Both the mean and the maxi-
mum dose to the brainstem were also less in the
3Dose plans (p = 0.001 and p = 0.01). However, there
was no difference in the maximum dose to the spinal
c o r do rt h ev o l u m eo ft i s s u en o to t h e r w i s es p e c i f i e d
r e c e i v i n g7 0G yb e t w e e nt h eR T O Ga n d3 D o s ep l a n s
(Table 5).
Discussion
Previous work from our group has suggested that early
assumptions that called for large volumetric expansions
on the high dose GTV may not improve locoregional
control of tumors. This retrospective study found that
volumetric expansions of ≤ 1.5 cm resulted in similar
locoregional control as greater expansions [1]. In the
report, direct GTV to PTV-HD expansions of 4-6 mm,
without the use of a high dose clinical target volume,
resulted in similar locoregional control as 10 - 15 mm
expansions or > 15 mm expansions. A recent abstract
from Sultanem et al., also reports satisfactory locoregio-
nal control and patterns of failure analysis without the
use of a high dose clinical target volume [3]. Different
institutional IMRT protocols may have an important
impact on these findings regarding the high dose GTV-
PTV expansion. For instance, the use of an intermediate
dose PTV is an important factor to consider.
In this study we examined the possible dosimetric
benefits of smaller target volumes. Utilizing a three dose
level plan resulted in a more homogenous dose to the
PTV-HD and PTV-ED, evidenced by improved 93% cov-
erage of each volume with concomitant decreases in
mean target doses and target volumes receiving 110% of
prescription doses. This may be due to the smaller total
target volume or the effect of the PTV-ID limiting dose
to the periphery of PTV-HD and central portion of
PTV-ED.
PTV-ID as used in the 3Dose plans serves a more
important role than just improving heterogeneity, how-
ever. As shown in Table 2 the intermediate volume was
identical to PTV-HD in RTOG plans. Any subclinical
disease beyond the GTV is, by definition, microscopic.
By replacing a high dose CTV with an intermediate
Table 3 Dose Constraints for Planning
Structure Maximum Minimum
PTV-HD <20% volume >110% Rx <1% volume <93% Rx
>95% volume >100% Rx
PTV-ID <1% volume <93% Rx
>95% volume >100% Rx
PTV-ED <1% volume <93% Rx
>95% volume >100% Rx
Parotid Mean dose <26 Gy or
50% volume <30 Gy
Cord <0.03 cc >48 Gy
Abbreviations: PTV-HD = high dose PTV; PTV-ID = intermediate dose PTV; PTV-
ED = elective dose PTV; Rx = prescription dose
Table 4 Planned Target Volume (PTV) Data
RTOG 3Dose p
Volumes (cc)
PTV-HD 293.6 111.6 <0.001
PTV-ED 704.8 545.2 <0.001
PTV Total 998.4 837.3 <0.001
Doses
PTV-ED heterogeneity (%)
110% 36.549 14.870 0.002
115% 15.086 2.716 <0.001
93% Target Coverage (%)
PTV-HD 99.823 99.994 0.049
PTV-ED 99.449 99.705 0.06
Mean Target Doses (cGy)
PTV-HD 7357.63 7240.90 0.01
PTV-ED 6099.57 5935.40 0.001
PTV Total 6468.31 6281.12 <0.001
Mean MUs 1675 1556 0.01
Abbreviations: RTOG = two dose level plan; 3Dose = three dose level plan;
PTV-HD = high dose PTV; PTV-ED = elective dose PTV; PTV Total = sum of
PTV-HD, PTV-ED, and PTV-ID; MUs = monitor units
Table 5 Normal Structure Doses
RTOG 3Dose P
Parotid
Mean (cGy) 2844.64 2631.30 0.01
V30 (%) 33.37 29.79 0.001
Mandible
Mean 4430.08 4125.83 0.001
V70 6.779 1.772 0.03
GSL Mean 6604.05 6223.56 <0.001
IPC Mean 6136.40 5645.61 0.001
Brainstem
Mean 1390.43 1300.14 0.001
Max 4609.93 4398.13 0.01
Cord Max 4284.28 4272.41 0.75
Tissue NOS V70 0.12145 0.04679 0.2
Abbreviations: RTOG= two dose level plan; 3Dose= three dose level plan; V30=
volume receiving 30 Gy or more; V70= volume receiving 70 Gy or more; GSL=
glottic and supraglottic larynx; IPC= inferior pharyngeal constrictor; Tissue
NOS= tissue within body not contoured as target volume or organ at risk
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marginal failures may be avoided while providing
improved toxicity outcomes. Additionally, Kashibatla et
al. suggested that the use of concurrent chemotherapy
provides a biological equivalent dose equal to a 12 Gy
dose escalation in 2 Gy daily fractions [4]. Therefore,
the delivery of 63 Gy with concurrent chemotherapy
may result in comparable tumor control probability. For
example, data from EORTC 24954 in advanced larynx
and hypopharynx cancers would further substantiate
this dose as 60 Gy split course radiotherapy with alter-
nating chemotherapy provided equivalent outcomes to
induction chemotherapy followed by 70 Gy of conven-
tional radiotherapy [5]. Future investigations will be
required to assess clinical outcomes with these proposed
volumes and doses.
Blanco et al. and Chao et al. estimated that 4 - 5% of
salivary function was lost for each additional 1 Gy in
mean dose to the parotid [6,7]. Thus the finding that
mean dose to the contralateral parotid was reduced 2.1
Gy in the 3Dose plans, from 28.4 Gy to 26.3 Gy (Table
5), may be a clinically significant amount. Four patients
achieved a mean dose less than 26 Gy with RTOG
plans, while the same 4 and one additional patient were
under this threshold in the 3Dose plans. Additionally,
the volume of the contralateral parotid receiving 30 Gy
was reduced from 33.4% to 29.8%, though all patients
met the < 50% parameter specified by RTOG 0522.
Currently, there is little data available regarding dose-
volume parameters for the mandible in order to avoid
osteoradionecrosis (ORN). Both Ben-David et al. and
Studer et al. found very low rates of ORN (<1%) in a
population treated with prophylactic dental care and
IMRT [8,9]. However, Eisbruch et al. reported a risk of
6% in early stage oropharyngeal patients treated with
IMRT on RTOG 0022 [10]. In two patients for whom
dosimetry was available, ORN occurred in the sites of
maximal dose, which approached 70 Gy in 30 fractions.
It is therefore reasonable to assume that reducing the
total dose and dose per fraction to the mandible will
result in reduced rates of osteoradionecrosis. Using
smaller target volumes, it is possible to significantly
reduce the mean mandible dose (absolute decrease of 3
Gy) as well as higher doses to the mandible (absolute
V70 decrease of 5%, Table 5).
Doses to both the GSL and IPC have been associated
with late swallowing toxicity [2,11-15]. Mean doses to
the GSL and IPC were reduced in the 3Dose plans,
although these structures were not constrained in our
planning process for either the RTOG or 3Dose plans.
Further reductions should theoretically be possible in
appropriate patients. For example, in the 6 patients
without a primary site in the larynx or hypopharynx, the
mean dose to the GSL was reduced 4.5 Gy, and the
mean dose to the IPC was reduced 5.3 Gy using 3Dose
target definitions.
Reductions in dose to the brainstem may reduce the
incidence of nausea and vomiting during treatment [16].
In the current study, the mean dose to the brainstem
was significantly less, though only by 90 cGy. The maxi-
mum dose to the brainstem was also reduced approxi-
mately by a mean of 2 Gy. These reductions likely are
not clinically significant, though an improvement
according to the “as low as reasonably achievable”
principle.
Conclusion
Investigations have suggested that patients may achieve
equivalent locoregional control with wide target volumes
as stipulated in various protocol regimens or more
restrictive target volumes with additional dose levels as
outlined herein. The present communication suggests
that target volume reductions (with an additional inter-
mediate dose level) may provide an enhanced therapeu-
tic ratio as critical structures may be spared and
patients may avoid debilitating toxicities. The refinement
of IMRT treatments, with or without chemotherapy, for
locoregionally head and neck cancer will require consid-
eration of the ideal target volumes that allow tumor
control while minimizing toxicity.
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